COGT vs RLAY
COGT: A clinical-stage biotechnology company developing precision protein kinase inhibitors for oncology and genetically defined diseases. RLAY: Relay Therapeutics is a precision medicine company leveraging a protein-motion discovery platform to develop targeted therapies for oncology and genetic diseases.
Side-by-side fundamentals
| Metric | COGT | RLAY | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $36.73 | $19.44 | |
| Market cap as of 2026-08-24 | $6.4B | $4.3B | |
| Net margin as of 2026-08-24 | -264.1% | -2047.2% | COGT higher |
| Operating margin as of 2026-08-24 | -295.8% | -2222.7% | COGT higher |
| ROE as of 2026-08-24 | -83.3% | -42.3% | RLAY higher |
| ROA as of 2026-08-24 | -55.8% | -38.7% | RLAY higher |
| Debt / equity as of 2026-08-24 | 0.37 | 0.00 | RLAY lower |
| Revenue growth (YoY) as of 2026-08-24 | n/a | +23.9% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +123.2% | |
| Beta as of 2026-08-24 | 0.31 | 1.70 | |
| 1-year return as of 2026-08-21 close | +212.1% | +470.1% | RLAY higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.